BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36584498)

  • 1. Characterization of the tumor-infiltrating lymphocyte landscape in sinonasal mucosal melanoma.
    Ledderose S; Schulz H; Paul T; Ledderose C; Ledderose GJ
    Pathol Res Pract; 2023 Jan; 241():154289. PubMed ID: 36584498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Tumor-Infiltrating Lymphocytes in Sinonasal Mucosal Melanoma.
    Ledderose S; Ledderose C; Penkava J; Ledderose GJ
    Laryngoscope; 2022 Jul; 132(7):1334-1339. PubMed ID: 34415055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer.
    Pereira MA; Ramos MFKP; Cardili L; de Moraes RDR; Dias AR; Szor DJ; Zilberstein B; Alves VAF; de Mello ES; Ribeiro U
    J Gastrointest Surg; 2024 Feb; 28(2):151-157. PubMed ID: 38445936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
    Hongo T; Yamamoto H; Jiromaru R; Yasumatsu R; Kuga R; Nozaki Y; Hashimoto K; Matsuo M; Wakasaki T; Tamae A; Taguchi K; Toh S; Masuda M; Nakagawa T; Oda Y
    Mod Pathol; 2021 Nov; 34(11):1966-1978. PubMed ID: 34218257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in 117 sinonasal mucosal melanomas and its association with clinical outcome.
    Wang L; Liu H
    Ann Diagn Pathol; 2022 Oct; 60():151976. PubMed ID: 35660809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
    Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y
    Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of tumor infiltrating lymphocytes in sinonasal mucosal melanoma and prognosis for patients.
    Yin G; Guo W; Liu H; Huang Z; Chen X
    Curr Probl Cancer; 2022 Aug; 46(4):100878. PubMed ID: 35752137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and Therapeutic Implications of Immune Classification by CD8
    García-Marín R; Reda S; Riobello C; Cabal VN; Suárez-Fernández L; Vivanco B; Álvarez-Marcos C; López F; Llorente JL; Hermsen MA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
    Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
    J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical role of CD274 (PD-L1) and CD3+ lymphocytes in predicting high risk in advanced colorectal cancer patients receiving neoadjuvant chemotherapy.
    Benek S; Zengin M
    Pol J Pathol; 2023; 74(2):98-108. PubMed ID: 37728469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.